Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
emvigorate: IV empasiprubart vs IVIg in CIDP
jRCT2051250110Phase 3Recruiting
- Sponsor
- argenx
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial of empasiprubart in chronic inflammatory demyelinating polyneuropathy (CIDP) (2 arms), sponsored by argenx. Primary endpoint: Reduction of ≥1 point in adjusted INCAT (aINCAT) score at week 24 vs baseline. Started Oct 2025; status: recruiting.
02
Drugs
empasiprubart
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on jRCT2051250110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250110.